Shire Recognizes Rare Disease Day 2014

Lexington, Massachusetts (ots/PRNewswire) -

Global Initiatives Underscore Shire's Long-term Commitment to the
Rare Disease Community

Shire plc today announced its support of Rare Disease Day and
invites others to join them in its continued commitment to the rare
disease community. Observed annually on the last day of February,
Rare Disease Day is coordinated at the international level by the
European Organisation for Rare Diseases (EURORDIS) and by National
Alliances and Patient Organizations at the national level.

There are estimated to be between 6,000 and 8,000 rare diseases
worldwide.[1] These diseases affect nearly 30 million people in the
US and approximately 30 million people in Europe.[1],[2] A disease or
disorder is classified as rare in Europe when it affects less than 1
in 2,000 people and in the U.S. when it affects fewer than 200,000
people.[1],[3] It is estimated that 75 percent of rare diseases
affect children, and 30 percent of rare disease patients will die
before the age of 5.[1]

The theme for this year's Rare Disease Day, "Join Together for
Better Care", encourages everyone supporting the rare disease
community to find ways to work together to help both patients and
their families find common solutions for care and remind them they
are not alone. Rare disease care has many facets and is a universal
need, and only through joining together will we find ways to provide
the different kinds of care that people living with rare diseases
need to improve their lives.

"On this important day, we show our commitment to the rare disease
community by joining forces to raise awareness of rare diseases
worldwide," said Jeff Poulton, Head of the Rare Disease Business Unit
at Shire. "Shire's purpose is to enable people with life-altering
conditions to lead better lives and so we support the efforts of Rare
Disease Day to better patient care. We hope that by working together
we can help ensure patients with rare diseases receive consistent,
reliable and effective treatments and services to meet their
individual needs."

Shire is sponsoring and participating in a variety of Rare Disease
Day activities, and partnering with local patient organizations
around the world, to help educate physicians and communities about
rare diseases and advocate for those whose lives are impacted. Some
of these initiatives include:

- The Global Genes Project with Wear That You Care(TM) to raise awareness of
rare genetic disorders;
- EURORDIS Roundtable of Companies on the topic of "Unlocking Europe's Potential
in Rare Disease Therapies" on February 26 in Brussels, Belgium;
- Rare Disease Day Legislative Advocates (RDLA) "Rare Disease Day Legislative
Conference and Lobby Day" from February 25-27th in Washington DC, US;
- Spanish Federation of Rare Diseases (FEDER) experts meeting on February 21st
and the official Rare Disease Day event on February 28th in Madrid, Spain;
- Lysosomal Storage Disease Department at the Queen Elizabeth Hospital in
Birmingham, UK, rare disease event;
- The 2nd National Editorial Award on Rare Disease and Rare Cancers organized by
OMAR (Observatory Rare Disease) in Italy;
- Rare Voices Australia (RVA) to hold a Rare Disease Day meeting, in partnership
with Wesley Hospital, in Brisbane, and assisting RVA in holding a Friends of Rare
Disease Parliamentary event at Parliament House in Canberra;
- Rare Disease Day activities organized by the non-profit organization Promotion
of Research on Intellectual Property (PRIP) Tokyo in Japan;
- Argentinean Federation of Rare Diseases (FADEPOF) awareness campaign
"Descubrinos, estamos aca" ("Discover us, we are here") and activities for Rare
Disease Day.

As a leader in rare diseases, Shire has a global focus on the
research, development, registration and marketing of therapies for
the treatment rare conditions.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better
lives.

Our strategy is to focus on developing and marketing innovative
specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases,
Gastrointestinal and Internal Medicine and we are developing
treatments for symptomatic conditions treated by specialist
physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical
facts are forward-looking statements. Forward-looking statements
involve a number of risks and uncertainties and are subject to change
at any time. In the event such risks or uncertainties materialize,
Shire's results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, that:

- Shire's products may not be a commercial success;
- revenues from ADDERALL XR are subject to generic erosion and revenues from
INTUNIV will become subject to generic competition starting in December 2014;
- the failure to obtain and maintain reimbursement, or an adequate level of
reimbursement, by third-party payors in a timely manner for Shire's products may
impact future revenues, financial condition and results of operations;
- Shire conducts its own manufacturing operations for certain of its Rare
Diseases products and is reliant on third party contractors to manufacture other
products and to provide goods and services. Some of Shire's products or ingredients
are only available from a single approved source for manufacture. Any disruption to
the supply chain for any of Shire's products may result in Shire being unable to
continue marketing or developing a product or may result in Shire being unable to do
so on a commercially viable basis for some period of time.
- the development, approval and manufacturing of Shire's products is subject to
extensive oversight by various regulatory agencies and regulatory approvals or
interventions associated with changes to manufacturing sites, ingredients or
manufacturing processes could lead to significant delays, increase in operating costs,
lost product sales, an interruption of research activities or the delay of new product
launches;
- the actions of certain customers could affect Shire 's ability to sell or
market products profitably. Fluctuations in buying or distribution patterns by such
customers can adversely impact Shire's revenues, financial conditions or results of
operations;
- investigations or enforcement action by regulatory authorities or law
enforcement agencies relating to Shire's activities in the highly regulated markets in
which it operates may result in the distraction of senior management, significant
legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire's
ability to enforce and defend patents and other intellectual property rights required
for its business, could have a material adverse effect on Shire's revenues, financial
condition or results of operations;
- Shire faces intense competition for highly qualified personnel from other
companies, academic institutions, government entities and other organizations. Shire
is undergoing a corporate reorganization and the consequent uncertainty could
adversely impact Shire's ability to attract and/or retain the highly skilled personnel
needed for Shire to meet its strategic objectives;
- failure to achieve Shire's strategic objectives with respect to the
acquisition of ViroPharma Incorporated may adversely affect Shire's financial
condition and results of operations;

and other risks and uncertainties detailed from time to time in
Shire's filings with the U.S. Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K.

References

1) EURORDIS. What is a rare disease? Factsheet. Available at:
http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf. Last
accessed February 2014.
2) NORD. Available at: http://www.rarediseases.org/about
3) National Institutes of Health. FAQ about rare diseases. Available at:
http://www.ncats.nih.gov/about/faq/rare/rare-faq.html. Last accessed February
2014.

For further information please contact:
Media
Lauren O'Brien
lobrien@shire.com
+41-22-419-4040

Gwen Fisher
gfisher@shire.com
+1-484-595-9836

ots Originaltext: Shire Pharmaceuticals Group Plc
Im Internet recherchierbar: http://www.presseportal.de